Foghorn Therapeutics Inc. (FHTX): Capital Expenditures
$50.0K
Year ended 2025-12-31
$50.0K
Trailing 12 months to 2026-06-30
-65.4%
3-year compound annual growth
-68.5%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.0K | -94.5% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $906.0K | -26.0% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $1.22M | +1.2% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $1.21M | -63.5% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $3.31M | -79.5% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $16.18M | n/m | 2022-08-09, From 2020-01-01 |
| 2019-12-31 | $968.0K | n/a | 2021-03-18, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $28.0K | n/a |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $567.0K | -89.1% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $2.35M | -16.9% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $177.0K | +168.2% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $756.6K | +0.5% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $174.5K | -89.5% |
Compare FHTX, VSTM, ZOMDF, BHST side by side · Screen every company in Pharmaceutical Preparations ↗